Sustained-Release Antimalarial Formulations for Seasonal Chemoprevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current malaria treatments often require frequent dosing and lack a widely available single-dose solution that provides sustained protection, posing challenges in maintaining high efficacy and simplifying patient compliance, especially in high-transmission seasons.
Innovation Solution
Development of new sustained release formulations, including depot formulations and suspension formulations comprising nanoparticles or microparticles of crystalline forms of ELQ-300, atovaquone, or pyronaridine, which are administered to provide prolonged antimalarial activity and can be given as a single oral or injectable dose for seasonal chemoprevention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent dosing is used to maintain high efficacy, then treatment effectiveness is improved, but patient compliance deteriorates
Solution Approach 1:
The patent segments the antimalarial treatment into multiple active ingredients (e.g., ELQ-300, atovaquone, pyronaridine) combined with specific excipients that control release rates. This segmentation allows different components to address different aspects: the active ingredients provide therapeutic effect while the excipient system provides sustained release, resolving the contradiction between maintaining effectiveness and improving compliance.
Solution Approach 2:
The patent employs preliminary action by formulating sustained-release compositions that pre-program the release of antimalarials over time. The excipient system is designed in advance to maintain drug release over extended periods (days to weeks), eliminating the need for frequent patient dosing while maintaining therapeutic levels, thus improving compliance without sacrificing effectiveness.
2Ease of operation
If single-dose formulations are used to improve compliance, then ease of administration is improved, but sustained protection deteriorates
Solution Approach 1:
The patent achieves continuity of useful action through sustained-release formulations where excipients control the gradual release of antimalarials from a single dose. The system maintains therapeutic drug levels continuously over extended periods (described as days to weeks), providing sustained protection while requiring only single administration, thus resolving the contradiction between ease of administration and duration of action.
Solution Approach 2:
The patent applies parameter changes by modifying the physical and chemical properties of the formulation system. Specific excipients are selected and combined in particular ratios to achieve desired release kinetics. The patent describes optimizing parameters such as release rate, particle size distribution, and excipient composition to transform a single dose into a sustained-release system that maintains therapeutic effectiveness over time.
3Duration of action of moving object
If sustained release formulations are developed to provide prolonged protection, then duration of action is improved, but device complexity deteriorates
Solution Approach 1:
The patent manages formulation complexity by systematically optimizing parameters of excipients and their combinations. Specific excipients are selected based on their release properties, and their ratios are optimized to achieve target release profiles. This parameter-based approach allows control of complex sustained-release behavior through manageable formulation variables, balancing prolonged protection with practical manufacturability.
Solution Approach 2:
The patent employs composite materials by combining multiple excipients with antimalarial active ingredients to create sustained-release formulations. The composite system leverages the complementary properties of different excipients (e.g., matrix formers, release modifiers, stabilizers) to achieve controlled drug release. This composite approach distributes the complexity across multiple functional components rather than requiring a single complex mechanism.
Data Source
AI summary
Provided herein are compounds, compositions and method of using thereof to treat or prevent malaria.